B12 vs Glycine in Compounded Tirzepatide: Which Additive Is Right for Your Patients?

Many compounded GLP-1 formulations include vitamin B12 (cyanocobalamin or methylcobalamin) or glycine as additives. For prescribers building GLP-1 programs, understanding the rationale for each additive — and the clinical considerations for choosing between them — helps you make better prescribing decisions and counsel patients more effectively.

From a regulatory standpoint, additives serve an important function: they help distinguish a compounded preparation from a "copy" of the branded product. The FDA's "essentially a copy" standard means that compounded preparations that are identical to commercially available products may not be permissible under 503A rules.

Adding a clinically justified ingredient — B12, glycine, or another component — creates a differentiated formulation with a legitimate clinical rationale. This is not just regulatory box-checking; both B12 and glycine have genuine clinical rationale in the context of GLP-1 therapy.

Fatigue and energy: GLP-1 therapy, particularly during the titration phase, is commonly associated with fatigue. B12 is essential for energy metabolism — it plays a central role in the conversion of food to cellular energy. Supplementing B12 alongside GLP-1 therapy may help mitigate fatigue.

Nausea support: B12 (particularly in its pyridoxine-adjacent role in neurological function) may help reduce nausea. While the evidence is not as strong as for pyridoxine (B6) specifically, many patients report subjective improvement.

Neurological support: B12 is essential for myelin synthesis and neurological function. Patients on calorie-restricted diets during GLP-1 therapy may have reduced dietary B12 intake.

Metformin interaction: Many GLP-1 patients are also on metformin for T2D. Metformin is well-documented to reduce B12 absorption. Co-prescribing B12 addresses this interaction.

Cyanocobalamin: The synthetic form of B12. Less expensive, more stable. Must be converted to active forms (methylcobalamin, adenosylcobalamin) in the body. Suitable for most patients.

Methylcobalamin: The active form of B12. Does not require conversion. Preferred for patients with MTHFR gene variants that impair B12 metabolism, and for patients with neurological symptoms.

Some reports have noted potential compatibility concerns when B12 is mixed with certain GLP-1 formulations. Practices should source from compounders who have tested their specific formulations for compatibility and stability. Always request a COA that includes stability data for the complete formulation.

Muscle preservation: One of the concerns with GLP-1 therapy is the loss of lean muscle mass alongside fat loss. Glycine is a conditionally essential amino acid that plays a role in muscle protein synthesis. Supplementing glycine during GLP-1 therapy may help preserve lean mass.

Digestive support: Glycine is involved in bile acid conjugation and may support digestive function. Given that GLP-1 therapy slows gastric emptying and can cause GI side effects, glycine's digestive support role is clinically relevant.

Anti-inflammatory effects: Glycine has anti-inflammatory properties, which may be beneficial in the context of obesity-related systemic inflammation.

Sleep quality: Some research suggests glycine supplementation improves sleep quality — relevant for GLP-1 patients who may experience sleep disruption during titration.

Collagen synthesis: Glycine is the most abundant amino acid in collagen. During weight loss, skin laxity can be a concern. Glycine support for collagen synthesis may help maintain skin quality.

Some compounders offer formulations that include both B12 and glycine. The rationale: the two additives address different aspects of GLP-1 side effect management and metabolic support, and their combination provides more comprehensive support than either alone.

Considerations for hybrid formulations:

• Ensure the compounding pharmacy has tested the complete formulation for stability and compatibility
• The formulation should be documented in the prescription and patient record
• Patients should be counseled on all components

Whatever additive you choose, document the clinical rationale in the patient record. This serves both the regulatory purpose (demonstrating the formulation is not "essentially a copy") and the clinical purpose (creating a record of your prescribing rationale).

Request portal access →

This content is for informational and educational purposes only. It does not constitute medical advice. Prescribers should use clinical judgment when selecting formulations for individual patients.